The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Current Therapeutic Strategies and Novel Approaches in Osteosarcoma
Open accessAbstract
Osteosarcoma is the most frequent malignant primary bone tumor and a main cause of cancer-related death in children and adolescents. Although long-term survival in localized osteosarcoma has improved to about 60% during the 1960s and 1970s, long-term survival in both localized and metastatic osteosarcoma has stagnated in the past several decades. Thus, current conventional therapy consists of multi-agent chemotherapy, surgery and radiation, which is not fully adequate for osteosarcoma treatment. Innovative drugs and approaches are needed to further improve outcome in osteosarcoma patients. This review describes the current management of osteosarcoma as well as potential new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 3×
“The overall survival rate of these patients ranges from 10% to 50% [7,54,55], while that of patients with localized osteosarcoma is around 60% to 70% [27,85,86].”
BackgroundYeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · cited 1×
“Src activates tumor cell-motility and invasion [125].”
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.030 · Cited by 456
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Meyers, P. A., & Gorlick, R. (1997) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70540-x · Cited by 299
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., Rose, P. S., Folpe, A. L., & Laack, N. N. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.01.015 · Cited by 298
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Proton‐based radiotherapy for unresectable or incompletely resected osteosarcoma
Ciernik, I. F., Niemierko, A., Harmon, D. C., Kobayashi, W., Chen, Y., Yock, T. I., Ebb, D. H., Choy, E., Raskin, K. A., Liebsch, N., et al. (2011) · Cancer · doi:10.1002/cncr.26037 · Cited by 191 · cited 2×
“Proton therapy was conducted in a total of 55 patients with unresectable or partially-resected osteosarcoma in a study carried out at Massachusetts General Hospital [96].”
BackgroundLamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4130 · Cited by 181 · cited 1×
“Moreover, OPG indirectly induced both the prevention of tumor-induced osteolysis and the inhibition of tumor-associated development that improved overall survival rate in osteosarcoma in vivo [174].”
BackgroundSelf-citationOry, B., Heymann, M., Kamijo, A., Gouin, F., Heymann, D., & Redini, F. (2005) · Cancer · doi:10.1002/cncr.21530 · Cited by 169
Self-citationImpact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk
Matsunobu, A., Imai, R., Kamada, T., Imaizumi, T., Tsuji, H., Tsujii, H., Shioyama, Y., Honda, H., Tatezaki, S., & for the Working Group for Bone and Soft Tissue Sarcomas (2012) · Cancer · doi:10.1002/cncr.27451 · Cited by 158 · cited 2×
“Moreover, the 5-year LC and overall survival rates for 78 patients with unresectable osteosarcoma of the trunk were 61% and 32%, respectively [97].”
BackgroundVilella-Bach, M., Nuzzi, P., Fang, Y., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.7.4266 · Cited by 154 · cited 2×
“The mammalian target of rapamycin (mTOR), a serine-threonine protein kinase, induces the progression from the G1 to the S phase of the cell cycle [129].”
Background
Cited by
Li, H.-Y., Zhang, J., Sun, L.-L., Li, B.-H., Gao, H.-L., Xie, T., Zhang, N., & Ye, Z.-M. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.543 · Cited by 284
Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
Liu, K., Ren, T., Huang, Y., Sun, K., Bao, X., Wang, S., Zheng, B., & Guo, W. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.422 · Cited by 264
Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma
Li, M., Lu, Y., Long, Z., Li, M., Kong, J., Chen, G., & Wang, Z. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100236 · Cited by 27
Zheng, Y., He, Z., Su, Z., Wang, H., Jiang, X., Fang, X., Lu, S., & Li, Y. (2023) · Cell Biology International · doi:10.1002/cbin.12021 · Cited by 10
“The 5‐year overall survival rate of patients with OS has increased to 70% due to novel adjuvant chemotherapeutic methods and improvement in surgical treatment (Ando et al., 2013).”
Background
Metadata
- Authors
- Ando, K., Heymann, M.-F., Stresing, V., Mori, K., Rédini, F., & Heymann, D.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2013-05-24
- Volume
- 5
- Issue
- 2
- Pages
- 591-616
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W1967559772
- Cited by
- 234
- References
- 16
- FWCI
- 17.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.